glp 1 agonist microdosing GLP-1 Drugs: What To Know Microdosing of GLP-1's / Wellness

2019;29:320334.e5

The cardiovascular benefits, including reductions in MACE and stroke, also accumulate over time, with the most substantial gains observed within the first 24 to 36 months of treatment [124, 125]

Retatrutide is the first medication in this class that hits 3 different biological targets

However, the financial impact of the reported decrease in cardiovascular events has not yet been established (39)

Large cardiovascular outcome trials involving over 60,000 patients found no statistically significant increase in pancreatitis rates with GLP-1 agonists versus placebo

The interest in GLP-1 receptor agonists for weight management stems from their diverse mechanisms of action